Objectives: To determine whether covering an autologous bone grafts with three different barrier membranes prevents graft resorption, and to compare these membranes to each other.
Design: In 192 rats a standardised 4.0mm diameter bone graft was harvested from the right mandibular angle and transplanted to the left. Membranes used to cover the grafts were a new poly(DL-lactide-epsilon-caprolactone) membrane, a collagen and expanded polytetrafluoroethylene membrane. The controls were left uncovered. Graft resorption and incorporation were measured with transversal microradiography (TMR) in the four groups at 2, 4 and 12 weeks. Data were analysed using multiple regression analyses.
Results: Overall, there were no differences in modeling with resorption between the four groups. ePTFE at 12 weeks showed a lower mineralization ratio and graft height of the graft as compared to the other groups. The mean graft incorporation was progressive and nearly identical from 2 to 12 weeks in all groups.
Conclusions: Membranes have an equal effect on bone graft modeling and resorption as found in non-covered controls. Therefore, the indication to use a barrier membrane to prevent bone modeling with resorption and enhance incorporation of autologous onlay bone grafts is disputable.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.archoralbio.2009.02.010 | DOI Listing |
J Cancer Res Clin Oncol
January 2025
Sarcoma Unit, Department of Surgery, University Medical Center and Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
Purpose: The management of soft tissue sarcoma (STS) at reference centers with specialized multidisciplinary tumor boards (MTB) improves patient survival. The German Cancer Society (DKG) certifies sarcoma centers in German-speaking countries, promoting high standards of care. This study investigated the variability in treatment recommendations for localized STS across different German-speaking tertiary sarcoma centers.
View Article and Find Full Text PDFTransplant Cell Ther
January 2025
Dana-Farber Cancer Institute, Division of Transplantation and Cellular Therapy, Boston, MA. Electronic address:
Background: Post-transplant cyclophosphamide (PTCy) is a commonly used graft-vs-host disease (GVHD) prophylaxis, particularly in the setting of haploidentical (haplo) hematopoietic cell transplantation (HCT). The rate of graft failure has been reported to be as high as 12-20% in haplo-HCT recipients using PTCy. The objective of this study was to determine if donor type influenced the risk of late graft failure following RIC HCT using PTCy-based GVHD prophylaxis.
View Article and Find Full Text PDFAm J Sports Med
January 2025
Campbell Clinic Orthopedics, Germantown, Tennessee, USA.
Background: While allografts are commonly used for anterior cruciate ligament reconstruction (ACLR), evidence to guide specific allograft selection is lacking.
Purpose: To compare clinical and graft failure rates after ACLR using soft tissue-only allografts and bone-soft tissue allografts in adults.
Study Design: Systematic review and meta-analysis; Level of evidence, 4.
Exp Hematol Oncol
January 2025
Bone Marrow Transplantation Center of The First Affiliated Hospital Liangzhu Laboratory, Zhejiang University School of Medicine, No. 79 Qingchun Road, Hangzhou, Zhejiang, China.
Background: Sequential CD19 and CD22 chimeric antigen receptor (CAR)-T cell therapy offers a promising approach to antigen-loss relapse in relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL); however, research in adults remains limited.
Methods: This study aimed to evaluate the efficacy and safety of sequential CD19 and CD22 CAR-T cell therapy in adult patients with R/R B-ALL between November 2020 and November 2023 (ChiCTR2100053871). Key endpoints included the adverse event incidence, overall survival (OS), and leukemia-free survival (LFS).
J Nephrol
January 2025
Department of Medicine, Surgery and Neurosciences, Nephrology, Dialysis and Transplantation Unit, University Hospital of Siena, Siena, Italy.
Background: Renal functional reserve (RFR) measures the difference between the stimulated glomerular filtration rate (GFR) and the baseline GFR to detect early signs of renal functional decline. The protein load test (RFR-T) is the gold standard for RFR assessment but is a complicated procedure. Renal intraparenchymal resistance index (RRI) variation test (DRRI-T) is a non-invasive method to measure renal function reserve using ultrasound.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!